Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223

- PMLiVE

Biologic patent exclusivity scrapped in new US trade deal

Drugmakers dealt a blow in latest trade negotiations

- PMLiVE

AstraZeneca’s Calquence impresses in previously untreated CLL

Takes the fight to AbbVie/J&J’s Imbruvica

- PMLiVE

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category

- PMLiVE

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

US-based biotech is arguing the legal action is improper

AstraZeneca AZ

AstraZeneca divests Seroquel rights to focus on key therapy areas

Second divestment to Germany-based Cheplapharm this year

AstraZeneca AZ

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

Will go head-to-head with rival Roche's Tecentriq if approved

- PMLiVE

AstraZeneca wins FDA approval for Calquence in chronic lymphoma

Takes the fight to AbbVie and J&J's lymphoma rival Imbruvica

Bayer symbol

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Significantly reduced the risk of hospitalisation or cardiovascular death

- PMLiVE

Nucala works in rare inflammatory disease, says GSK

Company is planning to file for approval in indication next year

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

- PMLiVE

The long and winding road to asthma breakthroughs

Respiratory biologics are booming thanks to scientists who refused to be derailed by early research setbacks

AstraZeneca AZ

AstraZeneca launches $1bn Chinese investment fund

AZ is among the top investors in the country with a strong market presence

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links